USANA Health Sciences (NYSE:USNA) Raised to “Hold” at Zacks Research

USANA Health Sciences (NYSE:USNA) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, December 29th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, USANA Health Sciences has a consensus rating of “Reduce” and a consensus price target of $36.00.

USANA Health Sciences Stock Performance

USANA Health Sciences stock opened at $20.61 on Monday. USANA Health Sciences has a one year low of $18.48 and a one year high of $38.32. The company has a market cap of $376.75 million, a P/E ratio of 23.42, a price-to-earnings-growth ratio of 0.95 and a beta of 0.67. The business has a fifty day moving average of $20.72 and a two-hundred day moving average of $23.64.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.19. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.97%. The company had revenue of $226.20 million for the quarter, compared to the consensus estimate of $225.96 million. Sell-side analysts predict that USANA Health Sciences will post 2.45 EPS for the current year.

Hedge Funds Weigh In On USANA Health Sciences

Several large investors have recently bought and sold shares of USNA. National Bank of Canada FI raised its holdings in shares of USANA Health Sciences by 166.6% during the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after acquiring an additional 1,201 shares during the period. Tower Research Capital LLC TRC grew its position in USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after purchasing an additional 1,901 shares in the last quarter. CWM LLC raised its stake in USANA Health Sciences by 109.7% during the 2nd quarter. CWM LLC now owns 2,762 shares of the company’s stock valued at $84,000 after purchasing an additional 1,445 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in USANA Health Sciences by 52.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after purchasing an additional 1,327 shares during the period. Finally, Parallel Advisors LLC lifted its holdings in shares of USANA Health Sciences by 1,354.3% in the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after purchasing an additional 3,589 shares in the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.